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Crossing the Atlantic - The Euro-Lupus Nephritis Regimen in 
North America
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Francisco
2The Feinstein Institute for Medical Research, Manhasset
3Cliniques Universitaires Saint-Luc,Université catholique de Louvain, Brussels
More than a quarter century has passed since a landmark trial at the National Institutes of 
Health (NIH) established pulse intravenous cyclophosphamide (IVC) and high-dose 
glucocorticoids as the standard of care for active lupus nephritis (1). In the ensuing years, 
numerous other conventional and biologic therapies have been proposed and tested, most 
notably mycophenolate mofetil (MMF) (2) and rituximab (3), but none has been 
demonstrated to be superior to IVC during induction treatment of active disease.
Until new therapeutic strategies emerge that are proven superior to IVC, there will be a need 
for evidence-based best practices to guide the use of cyclophosphamide. For this reason, the 
Euro-Lupus Nephritis Trial (ELNT) compared two approaches to IVC treatment. One 
approach consisted of 44 weeks of IVC based on the NIH regimen, followed by maintenance 
therapy with azathioprine (AZA). The other approach consisted of just six biweekly 
infusions of IVC at lower doses (500 mg/infusion), followed by maintenance therapy with 
AZA (4,5). After 10 years of follow-up, efficacy was comparable in the two groups; the 
frequency of serious infectious complications was lower in the low-dose IVC group, but this 
advantage did not reach statistical significance. Despite the ELNT results, many lupus 
experts have been hesitant to adopt the modified regimen, citing concerns that the findings 
in a population of northern European, primarily Caucasian subjects might not be 
generalizable to other populations that tend to have more severe and refractory nephritis 
(e.g., Black and Hispanic patients).
A recent trial of abatacept for lupus nephritis (NCT00774852) has provided new data that 
may allay concerns about the generalizability of the ELNT regimen (6). The ACCESS trial, 
in which all subjects received the ELNT regimen as background therapy, was conducted in a 
North American study population that was 37% Black and 41% Hispanic. Although the trial 
did not demonstrate a benefit for abatacept, the result was striking in that the complete 
response (CR) rate in both treatment groups (with or without abatacept) was >30% at six 
months, which is higher than CR rates in other recent lupus nephritis trials (2,3). The high 
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response rate was particularly surprising given the racial and ethnic diversity within the 
study population.
We are keenly aware that it is hazardous to compare results from trials with different study 
designs and different study populations. Among other potential pitfalls, the studies do not all 
use the same criteria to define ‘complete response’. To address this problem, we applied the 
same response criteria to the raw data from ELNT, ACCESS, and the Aspreva Lupus 
Management Study (ALMS) (NCT00377637) (Table 1). In order to use data elements that 
were available from all three trials, we defined CR at 6 months as proteinuria <500 mg/24 
hours and no deterioration in serum creatinine relative to baseline. According to this 
analysis, the CR rates in all of the groups were strikingly similar. The MMF standard-of-
care regimen produced a CR rate of 21% in the ALMS trial. The high-dose IVC regimen 
produced a CR rate of 22% and 24% in the ALMS and ELNT trials, respectively. The low-
dose IVC regimen produced a response rate of 23% and 25% in the ACCESS and ELNT 
trials, respectively. This analysis does not resolve other potential pitfalls relating to 
differences between study populations. For example, the study populations in the three trials 
varied somewhat with respect to the severity of lupus nephritis as reflected by the frequency 
of nephrotic levels of proteinuria at baseline (Table 1). Nonetheless, the results are 
intriguing in the sense that they suggest that the ELNT regimen may be comparable to 
standard-of-care regimens consisting of high-dose IVC or MMF, even among the racially 
and ethnically diverse population in the ACCESS trial. While these findings do not 
definitively establish that the ELNT regimen is comparable to current standard-of-care 
regimens, they provide an evidence-based rationale for reconsidering the doubts that have 
heretofore made some clinicians reluctant to employ the low-dose IVC regimen.
How might we explain the surprising observation that a therapeutic regimen with less 
exposure to cyclophosphamide might have the same efficacy as a regimen with much greater 
exposure? Perhaps six months is not long enough to detect differences among the regimens, 
although the data on that point from the 5- and 10-year follow-up of the ELNT trial, suggest 
otherwise (4,5). Alternatively, when a comparison of several immunosuppressive induction 
regimens fails to identify any one that is superior to the others, we must consider the 
heretical possibility that none of the immunosuppressive drugs adds benefit to 
corticosteroids alone during the early stages of induction therapy. In this regard it is 
noteworthy that each of the trials compared in Table 1 rested on a foundation of 
glucocorticoid use. The ELNT trial began with three daily intravenous pulses of 
methylprednisolone (750 mg/day) followed by oral glucocorticoid therapy at an initial dose 
of 0.5 – 1.0 mg/kg/d depending on the severity of renal disease. After four weeks at the 
initial dose, the glucocorticoid dose was tapered by 2.5 mg every two weeks to an eventual 
maintenance dose of 5.0 – 7.5 mg/d (4). In both the ALMS (2) and ACCESS (6) trials, 
prednisone was begun at 60 mg/d and then tapered gradually to a maintenance dose of 10 
mg/d.
Finally, in mice depletion of B cells by cyclophosphamide is followed by emergence of 
autoreactive B cells during reconstitution of the B cell repertoire (7). In humans, B cell 
depletion promotes high levels of B-cell activating factor (BAFF) (8), and high levels of 
BAFF promote reconstitution of the B-cell compartment with a repertoire that is skewed 
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toward autoreactivity (9,10). Thus, the high-dose regimen may result in a continuous need 
for cyclophosphamide to delete newly generated autoreactive B cells, whereas the low-dose 
regimen with its early switch to AZA may have less impact on BAFF levels and might 
therefore be less likely to promote reemergence of autoreactive B cells. While this is at 
present only a speculation, it does raise the question of whether we may have adopted a 
therapeutic approach to the use of cyclophosphamide in which more aggressive treatment 
may actually have undermined the therapeutic goal and have led to the requirement for 
continued cyclophosphamide exposure. Based on available evidence, and the principle of 
first doing no harm, the ELNT regimen should be considered an option for all lupus 
nephritis patients.
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Table 1
Complete response rates in the Euro-Lupus Nephritis Trial (ELNT), the ACCESS Trial, and the Aspreva 
Lupus Management Study (ALMS), using the same response criteria. Analysis of study subjects with 
proteinuria >1 gm/24 hours at baseline.
Proteinuria at Baseline* Complete Response Rate†
(>3 gm/24 hr) (at 6 mos)
ELNT–Low dose (n=36) 42% 25%
ELNT–High dose (n=38) 45% 24%
ACCESS (n=66) 52% 23%
ALMS-MMF (N=169) 57% 21%
ALMS-CTX (N=171) 60% 22%
*
Percent of subjects with proteinuria >3 gm/24 hours at baseline. [All subjects with proteinuria >1 gm/24 hours at baseline were included in the 
analysis.]
†Complete response was defined as proteinuria ≤0.5 gm/24 hours and no deterioration in serum creatinine (defined as no more than 0.2 mg/dL 
increase compared to baseline)
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